

PATENT #3  
ATTORNEY DOCKET NO. 50304/091001Certificate of Mailing: Date of Deposit: August 30, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Heidi Wright  
Printed name of person mailing correspondence

  
Signature of person mailing correspondence

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FRESON et al.	Art Unit:	To Be Assigned
Serial No.:	10/542,238	Examiner:	To Be Assigned
Filed:	July 15, 2005	Customer No.:	21559
Title:	INHIBITION OF PACAP SIGNALING FOR THE PREVENTION AND TREATMENT OF THROMBOCYTOPENIA		

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Copies of an International Search Report, a Written Opinion of the International Search Authority, and an International Preliminary Report on Patentability issued in connection with a corresponding international application are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is


material to patentability.

This statement is being filed within three months of the filing date of the application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 30 August 2005

  
\_\_\_\_\_  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/091001
	Serial No.	10/542,238
	Applicant	FRESON et al.
	Filing Date	July 15, 2005
	Group	To Be Assigned
	IDS Filed	August 30, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/23420	04/05//01	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Cox et al., "VIP Elevates Platelet Cyclic AMP (cAMP) Levels and Inhibits In Vitro Platelet Activation Induced By Platelet-Activating Factor (PAF)," <i>Peptides</i> , 5:325-328 (1984).					
	Freson et al., "The Pituitary Adenylate Cyclase-Activating Polypeptide Is a Physiological Inhibitor of Platelet Activation," <i>The Journal of Clinical Investigation</i> , 113:905-912 (2004).					
	International Search Report (PCT/EP2004/001209)					
	Written Opinion of ISA (PCT/EP2004/001209)					
	International Preliminary Report on Patentability (PCT/EP2004/001209)					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	